Research Article
Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry
Table 3
Comparison of clinical characteristics of patients on VKA or DOAC prior admission after propensity score matching.
| | | Patients on prior VKA | Patients on prior DOAC | value | | N = 232 | N = 232 |
| | Demographic | | Male sex, n (%) | 139 (59.9) | 127 (54.7) | 0.260 | | Age (years), median (IQR) | 80 (72–87) | 81 (73–86) | 0.575 | | Body mass index (kg/m2), median (IQR) | 28.0 (25.1–31.6) | 27.3 (24.3–31.0) | 0.445 | | Baseline comorbidities, n (%) | | Hypertension | 189 (81.5) | 178 (76.7) | 0.209 | | Diabetes mellitus | 61 (26.3) | 74 (31.9) | 0.184 | | Heart failure | 15 (6.5) | 14 (6.0) | 0.848 | | Stroke/TIA | 42 (18.1) | 47 (20.3) | 0.555 | | Chronic kidney disease | 31 (13.4) | 31 (13.4) | 1.000 | | Vascular disease | 33 (14.2) | 34 (14.7) | 0.895 | | Hypercholesterolemia | 112 (48.3) | 113 (48.7) | 0.926 | | Current smoking habit | 13 (5.6) | 9 (3.9) | 0.143 | | COPD/SAHS | 30 (12.9) | 29 (12.5) | 0.889 | | History of malignant disease | 38 (16.4) | 38 (16.4) | 1.000 | | Dysthyroidism | 18 (7.8) | 17 (7.3) | 0.860 | | Any dependency level | 68 (29.3) | 72 (31.0) | 0.686 | | Concomitant treatment at admission, n (%) | | Beta-blockers | 103 (44.4) | 124 (53.4) | 0.042 | | ACEi/ARBs | 130 (56.0) | 123 (53.0) | 0.703 | | Antiplatelet therapy | 24 (10.3) | 27 (11.6) | 0.656 | | Laboratory parameters at admission | | Creatinine (mg/dL), median (IQR) | 1.19 (0.87–1.56) | 1.13 (0.87–1.56) | 0.628 | | Hemoglobin (g/dL), median (IQR) | 13.0 (12.0–14.0) | 13.0 (11.0–14.0) | 0.853 | | Platelet count (×109/L), median (IQR) | 178.0 (138.0–244.8) | 176.0 (134.0–233.0) | 0.432 | | Elevated D-dimer, n (%) | 121 (52.2) | 118 (50.9) | 0.954 | | Elevated procalcitonin, n (%) | 45 (19.4) | 40 (17.2) | 0.795 | | Elevated C-reactive protein, n (%) | 209 (90.1) | 210 (90.5) | 0.984 | | Elevated troponins, n (%) | 35 (15.1) | 31 (13.4) | 0.711 | | Elevated transaminases, n (%) | 86 (37.1) | 66 (28.4) | 0.138 | | Elevated ferritin, n (%) | 75 (32.3) | 61 (26.3) | 0.344 | | Elevated lactate dehydrogenase, n (%) | 167 (72.0) | 150 (64.7) | 0.182 |
|
|
ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; IQR, interquartile range; TIA, transient ischemic attack; COPD/SAHS, chronic obstructive pulmonary disease/sleep apnea-hypopnea syndrome. Coronary artery disease and/or peripheral artery disease. |
